Document is current
Any future updates will be listed below
-
Authors
McCubbin, Claire
Ryan, Joanne
Wu, Zimu
Vishwanath, Swarna
Owen, Alice J.
Espinoza, Sara E.
Woods, Robyn L.
Phyo, Aung Zaw Zaw https://orcid.org/0000-0002-8834-4072
-
Funding
Funding for this research was provided by:
National Institute on Aging and the National Cancer Institute at the United States National Institutes of Health (U01AG029824)
National Institute on Aging and the National Cancer Institute at the United States National Institutes of Health (U19AG062682)
National Health and Medical Research Council of Australia (334047)
National Health and Medical Research Council of Australia (1127060)
Monash University
Victorian Cancer Agency
ANZ Trustees
Wicking Trust
Mason Foundation
NHMRC Leadership 1 Investigator Grant (2016438)
National Heart Foundation of Australia - Postdoctoral Fellowship (110205-2025_PDF)
Monash University
- License Information
-
More Information
Article History
Received: 22 February 2026
Accepted: 27 March 2026
First Online: 10 April 2026
Declarations
:
: All individual participants of the ASPREE, ASPREE-XT and ALSOP studies signed informed consent on participation.
: All authors gave their approval for submission.
: The data for the present secondary data analysis study were from a 5-year ASPREE clinical trial and follow-on observational study (ASPREE-XT) – Trial Registration: International Standard Randomized Controlled Trial Number Register (ISRCTN 83772183) and clinical trials.gov (NCT 01038583). The ASPREE trial in Australia was approved by multiple Institutional Review Boards with primary ethics approval granted by the Monash University Human Research Ethics Committee (CF07/3730–2006/745MC). In Australia, the ASPREE-XT study received ethics approval from the Human Research Ethics Committee of Alfred Health (HREC/17/Alfred/198); The University of Tasmania (H0017149); Monash University (12771); ACT Health (ETH.3.18.037E); and The University of Adelaide (32802). ALSOP received ethics approval from this committee (Social ALSOP: CF11/1935–2011001094).All studies were conducted in accordance with the Declaration of Helsinki (1964, revised 2008), NHMRC Guidelines on Human Experimentation, the federal patient privacy (HIPAA) law and ICH-GCP and International Conference of Harmonization Guidelines for Good Clinical Practice. The current study was approved by the Monash University Human Research Ethics Committee (MHREC 47720).
: No animals were used for this research. The study on humans was conducted in accordance with the Declaration of Helsinki 2008 revision, NHMRC Guidelines on Human Experimentation, the federal patient privacy (HIPAA) law, the International Conference of Harmonisation Guidelines for Good Clinical Practice, and the Code of Federal Regulations. ASPREE also follows the Code of Federal Regulations as it relates to areas of clinical research. The overall management and conduct of the ASPREE clinical trial are the responsibility of the ASPREE Steering Committee.
: The authors declare no competing interests.
